Figure 4 | Scientific Reports

Figure 4

From: CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway

Figure 4

Anti-proliferative effects of gemcitabine and 5-FU combined with CG200745 in SNU-1196/GR. (a) SNU-1196/GR cells were treated with gemcitabine with or without CG200745. The IC50 of gemcitabine decreased from 2.291 to 0.209 μM at 0.25 μM CG200745 and to 0.048 μM at 0.5 μM CG200745; the value also decreased in SNU-1196/GR cells treated with 5-FU with or without CG200745 from 229.0 to 35.481 μM at 0.25 μM CG200745, to 6.761 μM at 0.5 μM CG200745, and to 0.417 μM at 1.0 μM CG200745. (c,d) Treatment of SNU-1196/GR cells with CG200745 increased cleaved-Caspase-3 and PARP levels and induced apoptosis

Back to article page